i-screen is APAC's largest direct-to-consumer pathology platform by volume, with over 145,000 users and more than 1.1 million lab tests conducted. The company delivers preventive health intelligence across Australia, Singapore, New Zealand, and the United Kingdom, combining comprehensive biomarker panels (65+ markers) with genomic, microbiome, and metabolomic analysis, all interpreted through an AI copilot and supported by licensed clinician oversight.

Built on a decade-long longitudinal multi-omic dataset, i-screen enables individuals and practitioners to shift from reactive healthcare to predictive, personalised prevention. The platform integrates wearable device data, digital vitals, and continuous glucose monitoring to build a complete picture of each user's health trajectory over time.

i-screen operates a practitioner network of ~4,000 healthcare providers across Southeast Asia and partners with leading wearable technology companies to bridge consumer wellness with clinical-grade diagnostics.